Company / Operating Cash Flow per Share
GT Biopharma, Inc. Operating Cash Flow per Share History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$0.89
FY2020
5-year range
-$18.52 / -$0.00
FY2016-FY2020
Trend
+95.2%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow per Share returned to growth in FY2020 after 3 years of decline, reaching $-0.89.
Based on SEC 10-K filings.
-0.89 in FY2020.
Improved from $-1.94 to $-0.89 over the past 4 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, operating cash flow per share increased 95.2% year-over-year.
- Peak operating cash flow per share was recorded in FY2014.
- Lowest operating cash flow per share in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | -$0.89 | +95.2% |
| FY2017 | -$18.52 | -854.4% |
| FY2016 | -$1.94 | -162.6% |
| FY2015 | -$0.74 | -95716.1% |
| FY2014 | -$0.00 | +60.9% |
| FY2013 | -$0.00 | +44.9% |
| FY2012 | -$0.00 | +65.2% |
| FY2011 | -$0.01 | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026